Injectable administration privileges among pharmacists in the United States

Oji, Valerie; McKoy-Beach, Yolanda; Pagan, Tiffany; Matike, Barbara; Akiyode, Oluwaranti

doi:10.1093/ajhp/69.22.2002

Cited by 7 publications

(7 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pharmacy-delivered injection may or may not be available to patients based on drug formulation, site of injection, and state-by-state regulation. 26…”

Section: Resultsmentioning

confidence: 99%

Perceptions of Long-Acting Injectable Antiretroviral Treatment Regimens in a United States Urban Academic Medical Center

Koren

Fedkiv

Zhao

et al. 2020

J Int Assoc Provid AIDS Care

View full text Add to dashboard Cite

Patient acceptance of long-acting injectable antiretroviral (LAI-ARV) HIV-1 regimens will determine uptake. Although previous literature reports high satisfaction, these data stem from clinical trials subject to selection bias. This cross-sectional survey from the HIV practices of an urban academic medical center assessed perceptions and preferences using Likert scales toward overall acceptability, proposed frequencies, injection-site reaction durations, and distribution venue. 59% of surveys were completed resulting 202 respondents. 60% were male, 72% black, and the median age was 49 (IQR 36-58). 93% reported a once daily tablet frequency, 69% reported single tablet regimens, and 59% reported missing zero doses in the prior 30 days. Patients self-categorized as likely (57%) or unlikely (43%) to accept LAI-ARV. Both decreasing frequencies between injections and durations of injection-site reactions resulted higher acceptability scores. 57% of respondents preferred receiving an injectable from their clinician’s office over other potential options. These data demonstrate positive LAI-ARV acceptance potential.

show abstract

“…Pharmacy-delivered injection may or may not be available to patients based on drug formulation, site of injection, and state-by-state regulation. 26…”

Section: Resultsmentioning

confidence: 99%

Perceptions of Long-Acting Injectable Antiretroviral Treatment Regimens in a United States Urban Academic Medical Center

Koren

Fedkiv

Zhao

et al. 2020

J Int Assoc Provid AIDS Care

View full text Add to dashboard Cite

show abstract

“…We are unaware of any studies that have evaluated consumer perceptions of community pharmacist administration of non-immunization injectable medications. This may be because pharmacist administration of injectable medications (besides vaccines) is currently not a privilege that is granted within many states' collaborative practice regulations at this time, and is therefore not widely implemented in practice; 8,19 however, patients have demonstrated general comfort, trust, and acceptance of community pharmacist-administered vaccinations, 20 a service that highly resembles this expanded service.…”

Section: Discussionmentioning

confidence: 99%

Building the Case: Changing Consumer Perceptions of the Value of Expanded Community Pharmacist Services

Steckowych

Smith

Spiggle

et al. 2018

Journal of Pharmacy Practice

View full text Add to dashboard Cite

Consumer unfamiliarity with non-traditional community pharmacist services is likely an influencer of consumers' hesitancy to utilize such services; therefore, an opportunity exists to engage consumers and advocacy organizations in supporting expanded community pharmacist roles. This study can inform consumers, advocates, community pharmacists, primary care providers, and community-based organizations on methods to shape consumer perceptions on the value of community pharmacist expanded services.

show abstract

“…Minimizing any barriers to receiving a monthly dose could conceivably encourage longer retention, especially in patients where difficulties with access may be playing a role in the early discontinuation. At least 21 US states currently grant privileges to pharmacists for the administration of non-vaccine injectable medications, including extended-release naltrexone [92]. While pharmacy remuneration, education, consistency in state law, and client awareness have all been identified as barriers in helping pharmacies administer injectable medications, anecdotal reports of community pharmacies establishing extended-release naltrexone programs for patients with OUD do exist [93, 94].…”

Section: Dispensing Of Medications For the Treatment Of Opioid Use DImentioning

confidence: 99%

Leveraging the role of community pharmacists in the prevention, surveillance, and treatment of opioid use disorders

Bach

Hartung

2019

Addict Sci Clin Pract

View full text Add to dashboard Cite

The global rise in opioid-related harms has impacted the United States severely. Current efforts to manage the opioid crisis have prompted a re-evaluation of many of the existing roles in the healthcare system, in order to maximize their individual effects on reducing opioid-associated morbidity and preventing overdose deaths. As one of the most accessible healthcare professionals in the US, pharmacists are well-positioned to participate in such activities. Historically, US pharmacists have had a limited role in the surveillance and treatment of substance use disorders. This narrative review explores the literature describing novel programs designed to capitalize on the role of the community pharmacist in helping to reduce opioid-related harms, as well as evaluations of existing practices already in place in the US and elsewhere around the world. Specific approaches examined include strategies to facilitate pharmacist monitoring for problematic opioid use, to increase pharmacy-based harm reduction efforts (including naloxone distribution and needle exchange programs), and to involve community pharmacists in the dispensation of opioid agonist therapy (OAT). Each of these activities present a potential means to further engage pharmacists in the identification and treatment of opioid use disorders (OUDs). Through a careful examination of these approaches, we hope that new strategies can be adopted to leverage the unique role of the community pharmacist to help reduce opioid-related harms in the US.

show abstract

Injectable administration privileges among pharmacists in the United States

Cited by 7 publications

References 5 publications

Perceptions of Long-Acting Injectable Antiretroviral Treatment Regimens in a United States Urban Academic Medical Center

Perceptions of Long-Acting Injectable Antiretroviral Treatment Regimens in a United States Urban Academic Medical Center

Building the Case: Changing Consumer Perceptions of the Value of Expanded Community Pharmacist Services

Leveraging the role of community pharmacists in the prevention, surveillance, and treatment of opioid use disorders

Contact Info

Product

Resources

About